Will PureHealth Seal a Second Major European Deal?

Dubai: Abu Dhabi-based healthcare conglomerate PureHealth is reportedly eyeing its second consecutive acquisition in Europe, this time targeting Portugal’s Luz Saude, a prominent hospital operator.

Luz Saude manages 20 hospitals across Portugal and Madeira, and the potential acquisition could significantly strengthen PureHealth’s European footprint. This move follows its earlier investment in Hellenic Healthcare Group, which operates hospitals in Greece and Cyprus.

“If the Luz Saude deal materializes, it would be a strategic addition for PureHealth, which has been vocal about its ambitions to become a global healthcare leader,” said a healthcare industry analyst.

Luz Saude is currently owned by Fidelidade, a firm controlled by China’s Fosun and Caixa Geral de Depósitos. Bloomberg was the first to report on the possible acquisition talks.

Will the Portugal deal go through?

Industry sources emphasize that PureHealth remains disciplined and valuation-sensitive in all its acquisition efforts.

“PureHealth has a track record of being highly selective with its investments. It prioritizes long-term value over speed and avoids rushing into deals,” the analyst added. “This measured approach is consistent with how the group has handled previous acquisitions both within the UAE and globally.”

Global expansion boosts revenue

In the first quarter of 2025, PureHealth reported a 7.6% increase in revenue, reaching Dh6.58 billion. This growth was bolstered by its UAE portfolio as well as recent acquisitions in the US and UK. Net profit for the quarter stood at Dh505 million.

Price remains the key factor

While PureHealth has yet to comment publicly on its intentions regarding Luz Saude, analysts following the ADX-listed firm underline that price will be the deciding factor.

“If a target is not valued fairly, PureHealth has no hesitation in walking away,” said one analyst familiar with the company’s investment approach. “While international expansion is a goal, shareholder value remains paramount. PureHealth is not willing to compromise on returns.”